Navigation Links
BioMed Realty Trust to Report 2008 Fourth Quarter and Year-End Results

SAN DIEGO, Feb. 2 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced it will report results for its fourth quarter and year ended December 31, 2008 after the market closes on Wednesday, February 11, 2009.

Alan D. Gold, Chairman and Chief Executive Officer, and Kent Griffin, President and Chief Financial Officer, will host an investor conference call at 10:00 a.m. Pacific Time on Thursday, February 12, 2009 to discuss the company's financial results and operations for the year.

The call will be open to all interested investors either through a live audio web cast at the Investor Relations section of the company's web site at and at, or live by calling 800.299.7089 (domestic) or 617.801.9714 (international) with call ID number 80976360. The call will be archived for 30 days on both web sites. A telephone playback of the conference call will also be available from 3:00 p.m. Pacific Time on Thursday, February 12, 2009 through midnight Pacific Time on Tuesday, February 17, 2009 by calling 888.286.8010 (domestic) or 617.801.6888 (international) and using access code 78309388.

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(R). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed owns or has interests in 69 properties, representing 112 buildings with approximately 10.4 million rentable square feet, including approximately 1.4 million square feet of development in progress. The company also owns undeveloped land parcels adjacent to existing properties that it estimates can support up to 1.4 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at

SOURCE BioMed Realty Trust, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells
2. Origin BioMed Awarded Red Herring Top 100 Global Company
3. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
4. Bavarian Nordics Case Against Oxford BioMedica
5. BioLife Solutions Joins Prestigious Biomedical Excellence for Safer Transfusion Collaborative
6. BioMed Realty Trust Declares Fourth Quarter 2008 Common Stock and Preferred Stock Dividends
7. BioMed Realty Trust Promotes Kent Griffin to President
8. Alfred Mann Foundation for Biomedical Engineering Launches New Web Site Designed to Help University Researchers Bring Biomedical Advances to Market
9. BioFlorida Selects Collexis as the Primary Professional Network for its 200 Member Companies and Organizations
10. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
11. SpineSmith Partners Collaborates with University of Texas Biomedical Engineering Students to Develop Innovative Products
Post Your Comments:
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... -- Andrew D Zelenetz , ... Published recently in Oncology & ... Andrew D Zelenetz , discusses the fact ... placing an increasing burden on healthcare systems worldwide, ... the patents on many biologics expiring, interest in ...
Breaking Biology Technology:
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems is ... log work hours, for employers to make sure the right employees are actually signing ... ... ... ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... ...
(Date:6/2/2016)... -- The Department of Transport Management (DOTM) of ... US Dollar project, for the , Supply and ... and IT Infrastructure , to Decatur ... of Identity Management Solutions. Numerous renowned international vendors participated in ... was selected for the most compliant and innovative solution. ...
Breaking Biology News(10 mins):